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Abstract; 
Background; The short-term benefits of inhaled corticosteroids for patients with chronic obstructive pulmonary 
disease (COPD) are greater in patients with evidence of eosinophilic airway inflammation. This study was 
conducted to determine the frequency of blood eosiniphilia in patients with acute exacerbations of COPD. 
Objective: To determine the frequency of blood eosinophilia in chronic obstructive pulmonary disease 
exacerbations. Material and methods; A total of 159 patients with acute exacerbations of COPD were 
registered and their eosinophil count was done. All data was entered on SPSS-20 and analyzed. Setting: Study 
was conducted in the pulmonology department of Nishtar Hospital Multan. Study design: Descriptive cross 
sectional study. Sampling technique: Non probability consecutive. Results; Of these 159 study cases, 87 
(54.7%) were male patients while 72 (45.3%) were female patients. Mean age of our study cases was 57.87 ± 
8.99 years (with minimum age of our study cases was 44 years while maximum age was 70 years). Mean body 
mass index (BMI) of our study cases was 23.89 ± 2.74 kg/m
2
, 32 (20.1%) were overweight and 16 (10.1%) were 
obese. Smoking was seen in 48 (30.2%) patients and 5% were light smokers, 10.1% were  moderate smokers and 
15.1% were heavy smokers. Mean duration of COPD was 8.18 ± 2.34 years (with minimum duration of illness 
was 6 years while maximum duration was 14 years). Mean duration of acute exacerbation of COPD was noted to 
be 6.21 ± 1.71 days (ranging from 4 to 10 days). Blood eosinophilia was noted in 87 (54.7%) of our study cases.  
Conclusion; Blood eosinophil count is a promising biomarker of response to inhaled corticosteroids in patients 
with COPD and very high frequency of blood eosinophilia was noted in our study. Blood eosinophilia was 
significantly associated with increasing age, heavy smoking and duration of COPD.  
Keywords; Blood eosinophilia, COPD, acute exacerbations.  
Introduction: 
 Chronic obstructive pulmonary disease is a highly prevalent and progressive respiratory disease.1 
Although mortality for COPD is decreasing in developed countries,
2
 it remains a major cause of morbidity and 
mortality worldwide.
1 
 According to WHO estimates, 65 million people have moderate to severe chronic 
obstructive pulmonary disease. More than 3 million people died of COPD in 2005, which corresponds to 5% of 
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all deaths globally. The health, social and economic impact of COPD (the third leading cause of death in the 
United States) is high. In 2010, the global cost associated with COPD in the USA was 50 billion dollars, of 
which 20 billion of indirect costs and 30 billion of direct costs.3 These costs tend to increase in a way directly 
proportional to the severity of the illness and to moderate and severe exacerbations, especially those requiring 
hospitalization. 
  Chronic obstructive pulmonary disease is characterized by the presence of an airflow limitation that is 
not fully reversible, and is usually progressive and associated with an abnormal inflammatory response of the 
lungs to noxious particles or gases.4 Until recently, COPD was thought to cause only pulmonary abnormalities, 
but recent studies have demonstrated the presence of systemic and extra-pulmonary effects.
5
Acute exacerbations 
of chronic obstructive pulmonary disease are associated with substantial morbidity and mortality
4
and are 
heterogeneous with respect to inflammation6 and etiology.7An acute exacerbation of COPD is associated with 
increased frequency and severity of coughing. It is often accompanied by worsened chest congestion and 
discomfort. Shortness of breath and wheezing are present in many cases. Exacerbations may be accompanied by 
increased amount of cough and sputum productions and a change in appearance of sputum. Although primarily 
associated with asthma, eosinophilic airway inflammation is also present in 20-40% COPD patients.8 Previous 
studies have shown that a sputum eosinophilia is associated with a positive response to corticosteroid treatment 
in stable COPD,
9
 and the sputum eosinophil count can be used to titrate corticosteroid therapy to reduce 
exacerbations of COPD.
10
 Studies have also shown that peripheral blood eosinophil count is a valid biomarker of 
this pattern of inflammation.11,12  In a study conducted by Bafadhel M, McKenna S, Terry S, Mistry V, Reid 
C, Haldar P et al it was found that 28% of the COPD exacerbations were eosinophil-associated exacerbations 
and peripheral blood eosinophil was the biomarker.
11
 
In another study conducted by Bafadhel M, McKenna S, Terry S, Mistry V, Pancholi M, Venge P et al, it was 
found that in 85 (51.2%) COPD exacerbations out of 166 exacerbations blood eosinophil level was more than 2 
%.
12 
 
 
Method and material: 
All the patients of either sex aged; 30 – 70 years, were taken from pulmonology department with diagnosis of 
acute exacerbation of COPD with history of COPD for at least 5 years. Patients with co-existent congestive 
cardiac failure (confirmed by echocardiography showing EF less than 55%), co-existent asthma, co-existent 
pulmonary tuberculosis, co-existent pneumothorax, co-existent pleural effusion and patients with co-existent 
interstitial lung disease were excluded from our study. A total of 159 patients with acute exacerbation of COPD 
fulfilling inclusion and exclusion criteria were enrolled by non-probability consecutive technique. Demographic 
data like age (in years) and gender (male/female) was noted. Informed consent was taken from patients. All 
investigations were done from Nishtar Hospital Multan laboratory which includes complete blood count, sputum 
culture, chest radiograph, echocardiography and spirometery.  
 
Results; 
Our study included a total of 159 study cases meeting inclusion criteria of our study. Of these 159 study cases, 
87 (54.7%) were male patients while 72 (45.3%) were female patients. Mean age of our study cases was 57.87 ± 
8.99 years (with minimum age of our study cases was 44 years while maximum age was 70 years). Mean age of 
the male patients was 57.77 ± 8.35 years while that of female patients was 58.00 ± 9.76 years (p = 0.873). Our 
study results have indicated that majority of our study cases i.e. 119 (74.8%) were aged 51 – 70 years of age. 
Mean height of our study cases was 163.52 ± 10.21 centimeters while mean weight of our study cases was 61.34 
± 11.71 kilograms. Mean body mass index (BMI) of our study cases was 23.89 ± 2.74 kg/m2, 32 (20.1%) were 
overweight and 16 (10.1%) were obese. Smoking was seen in 48 (30.2%) patients and 5% were light smokers, 
10.1% were  moderate smokers and 15.1% were heavy smokers. Mean duration of COPD was 8.18 ± 2.34 years 
(with minimum duration of illness was 6 years while maximum duration was 14 years). our study results have 
documented that majority of these patients had disease duration ranging from 5 – 10 years. Mean duration of 
acute exacerbation of COPD was noted to be 6.21 ± 1.71 days (ranging from 4 to 10 days). Our study results 
have documented that majority of our patients i.e. 119 (74.8%) presented within one week.  Blood eosinophilia 
was noted in 87 (54.7%) of our study cases  
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Table No. 1 
Stratification of Blood eosinophilia with regards to duration of COPD.  
(n = 159) 
Duration of COPD 
Blood Eosinophilia 
P – value  Yes 
(n = 87) 
No 
(n = 72) 
5 – 10 Years 
(n = 128) 
64 64 
0.017 
More than 10 years 
(n= 31) 
23 08 
 
Total 
 
159 
 
Table No. 2 
Stratification of Blood eosinophilia with regards to acute exacerbation of COPD.  
(n = 159) 
Duration of acute 
exacerbation 
Blood Eosinophilia 
P – value  Yes 
(n = 87) 
No 
(n = 72) 
Up to 1 week 
(n = 119) 
63 56 
0.468 
More than 1 week 
(n= 40) 
24 16 
 
Total 
 
159 
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Discussion; 
Eosinophilic inflammation is thought to be a characteristic feature of asthma rather than COPD. However, 
studies have shown that a subset of COPD patients with eosinophilic airway inflammation exists, even after the 
careful exclusion of patients with any features of asthma, such as β-agonist reversibility, bronchial hyper-
responsiveness, atopy or a childhood history of asthma. Interestingly, these patients exhibit the greatest response 
to corticosteroid treatment
13-15
.  
Our study included a total of 159 study cases meeting inclusion criteria of our study. Of these 159 study cases, 
87 (54.7%) were male patients while 72 (45.3%) were female patients. Our results are consistent with that of 
findings of Zaman et al 
16
 from Peshawar who also reported overall male gender predominance in COPD 
patients. A study conducted by Waqas et al 
17
 has reported 70 % male patients predominating over female gender 
with 30 % frequency, these findings are similar to that of our study results. Hassan et al 18 reported 53 % male 
patients with COPD which is same as that of our study results. Motiani et al 
19
 reported 80 % male patients 
compared with 20 % female patients with COPD which is showing same trend as that of our study results. 
Mean age of our study cases was 57.87 ± 8.99 years (with minimum age of our study cases was 44 years while 
maximum age was 70 years). Mean age of the male patients was 57.77 ± 8.35 years while that of female patients 
was 58.00 ± 9.76 years (p = 0.873). Our study results have indicated that majority of our study cases i.e. 119 
(74.8%) were aged 51 – 70 years of age. Khan et al 
2
 also reported similar results. Phulpoto et al 
21
 reported 56.8 
± 7.8 years mean age of COPD patients, these findings are close to our study results. Motiani et al 
19
 reported 
60.87±10.93 years mean age of the patients, which is similar to that of our study results. Thakrar et al 22 reported 
63.54 ± 10.656 years mean age, which is close to our study results. Mean height of our study cases was 163.52 ± 
10.21 centimeters while mean weight of our study cases was 61.34 ± 11.71 kilograms. Mean body mass index 
(BMI) of our study cases was 23.89 ± 2.74 kg/m
2
, 32 (20.1%) were overweight and 16 (10.1%) were obese.  
Smoking was seen in 48 (30.2%) patients and 5% were light smokers, 10.1% were  moderate smokers and 15.1% 
were heavy smokers. Zaman et al 16 from Peshawar also reported 34 % smoking in these patients which is close 
to our study results and they also observed that all these smokers were male patients which is in compliance with 
that of our study results.  
Blood eosinophilia was noted in 87 (54.7%) of our study cases. A very recent study published in 2016 from 
America has reported 40 % blood eosinophilia which is close to our study results 23. A study conducted by 
Pascoe et al 
24
 also reported blood eosinophilia in 66% patients with acute exacerbations of COPD which is close 
to our results. In a study conducted by Bafadhel M et al it was found that 28% of the COPD exacerbations were 
eosinophil-associated exacerbations and peripheral blood eosinophil was the biomarker.11 In another study 
conducted, it was found that in 85 (51.2%) COPD exacerbations out of 166 exacerbations blood eosinophil level 
was more than 2 %.
12 
these results are in compliance with our study results.  
 
 
Conclusion;  
Blood eosinophil count is a promising biomarker of response to inhaled corticosteroids in patients with COPD 
and very high frequency of blood eosinophilia was noted in our study. Blood eosinophilia was significantly 
associated with increasing age, heavy smoking and duration of COPD.  
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